Xiaoxia Liu
Kun Han
Yunqin Wu- Department of Neurology, Ningbo No. 2 Hospital, Ningbo, China
Background: There is increasing research on the potential of inner ear proteins as serum biomarkers for the diagnosis and prognosis of various inner ear diseases. Among them, benign paroxysmal positional vertigo (BPPV) is the most common vestibular disease. Notably, otolin-1, an inner ear-specific protein, is detectable in the serum of most patients with BPPV patients. Therefore, we found a need to conduct this meta-analysis to determine the relationship between otolin-1 in serum and BPPV.
Methods: This meta-analysis was conducted by searching PubMed, EMBASE, Cochrane Library, Google Scholar, and China Network Knowledge Infrastructure databases for the eligible original studies in Chinese or English published between January 2010 and February 2022. Data were collected and pooled by using the mean differences (MDs) corresponding to 95% confidence intervals (CIs). Heterogeneity among these studies was assessed by using I2 statistics and the adopted fixed or random-effect mode thereafter. Egger's and Begg's tests were also used to assess the publication bias.
Results: This meta-analysis included six articles with a total of 585 participants. Serum otolin-1 levels were remarkably increased in patients with BPPV as compared to that in healthy controls (MD: 165.38, 95% CI: 110.13–220.64, p < 0.00001). However, Egger's and Begg's tests have indicated no publication bias, and the results were reliable based on the sensitivity analysis.
Conclusion: This meta-analysis indicated that there is a higher serum level of otolin-1 in patients with BPPV than in healthy controls. Therefore, otolin-1 may serve as a biomarker for the onset of BPPV.
Introduction
Benign paroxysmal positional vertigo (BPPV) is the most prevalent peripheral vestibular disease that is characterised by a sudden and transient onset of vertigo (1). It is the most common form of vertigo in older women in their fifties and sixties, with a male-to-female ratio of 1:2.4 (1, 2). Although the clinical symptoms may resolve spontaneously within days to weeks, BPPV has a reported recurrence rate of 7–50% and is associated with anxiety and reduced quality of life (3, 4). Current research asserts that BPPV involves the displacement of the otoconia, whereby the otoliths float into the semicircular canals or attach to the cupula, consequently increasing its sensitivity to gravity (5–7).
The diagnosis of BPPV heavily relies on the clinical history and the elucidation of positional nystagmus on the physical examination (1, 8). However, approximately 30% of BPPV cases are difficult to diagnose and treat, especially in cases of subjective BPPV or multiple canal involvements, which make it difficult to perform diagnostic positional manoeuvres (5, 9). Moreover, in situations where positional nystagmus cannot be elucidated after the patient is sent to the hospital, it is difficult to determine whether the patient is suffering from BPPV. Therefore, the identification of proteins that correspond to BPPV diagnosis may provide significant advances in early diagnosis, timely treatment, and potential prevention of complications.
Otolin-1, a scaffolding protein that is only expressed in the otoconia, vestibule, and cochlear cells, has been reported to be quantifiable in the blood serum (10, 11). It has also been found to increase with age, which could correspond with age-related otoconia degeneration (10, 12, 13). Interestingly, current research shows that otolin-1 levels in serum are elevated in patients with BPPV, indicating its potential as a biomarker for BPPV (10, 14–18).
Therefore, this meta-analysis aimed to review studies in this regard to further clarify the relationship between BPPV and otolin-1.
Methods
Study selection
The current review has included English or Chinese studies assessing the relationship between BPPV and otolin-1 levels in serum that were searched from the Cochrane Library, Google Scholar, EMBASE, PubMed, and China Network Knowledge Infrastructure databases between January 2010 and February 2022. The search terms included “otolin-1,” “BPPV,” “benign positional vertigo,” and “benign paroxysmal positional vertigo.” To reduce reviewer bias, two reviewers (KH and XL) carefully evaluated all potentially relevant articles thoroughly during the initial search strategy.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) all patients with BPPV tested for otolin-1, (2) diagnosis of BPPV based on the clinical history of recurrent positional vertigo and typical nystagmus during the Roll or Dix–Hallpike tests, and (3) original case–control studies.
The exclusion criteria were as follows: (1) non-original studies (e.g., case reports), (2) studies without a control group, (3) incomplete data or different study outcomes, and (4) overlapping subjects.
Data abstraction and quality assessment
Two reviewers (MZ and XL) extracted the following data from each study: the first author's name; publication year; study location and design; method of otolin-1 detection; the number of participants and patients; mean, average, and standard deviation of otolin-1 level; and the research results. The Newcastle–Ottawa Scale was used to assess the quality and the risk of bias of all included studies, ensuring that at the minimum, the articles with intermediate quality were included (19). Furthermore, the study quality was evaluated by the two reviewers (XL and YW), and any disagreements were resolved through discussion.
Statistical analyses
Mean differences (MDs) or standard mean differences (SMDs) with corresponding 95% confidence intervals (CIs) were used to evaluate the effect size, and study heterogeneity was tested using I2 statistics. If p ≥ 0.1 or I2 ≤ 50% indicated a lack of heterogeneity among studies, a fixed-effect model was used. On the contrary, a random effects model was used if p <0.1 or I2 > 50%. Sensitivity analyses were also performed based on the rule of omission to analyse heterogeneity. In addition, Egger's and Begg's tests were used to investigate publication bias.
Results
Study selection
A total of 153 publications were included using the initial search terms. After screening, only six studies with 585 participants were included for further evaluation. The selection process is summarised in Figure 1.
Figure 1. A flow diagram for the selection of studies.
Study characteristics
The included papers were all the case–control studies that analysed the association between BPPV and otolin-1 (Table 1). These studies were distributed in several regions, including China, India, and the United States (10, 14–18), with 281 patients with BPPV and 304 healthy controls. The clinical characteristics and research conclusions are presented in Table 1.
Table 1. Summary of the studies that investigated the association between BPPV and otolin-1 and quality assessment for case–control study.
Study findings
Since the heterogeneity among the included studies was high (I2 = 95%), the random-effects model was used (Figure 2). All six studies showed a significant association between BPPV and otolin-1 in terms of both MD (Figure 2.1, MD: 165.38, 95% CI: 110.13–220.64, p < 0.00001) and SMD effect size (Figure 2.2, SMD: 2.11, 95% CI: 1.06–3.16, p < 0.00001). Subgroup analysis based on the source of reagents and menopause was then performed to identify sources that may have contributed to heterogeneity. In this case, heterogeneity decreased significantly after subgroup analysis (Figures 3, 4; I2 = 50%, I2 = 76%), indicating that reagents and oestrogen levels could be the primary source of heterogeneity.
Figure 2. Forest plot of the association between BPPV and otolin-1 using the MD (1) and SMD (2) effect sizes. And as was showed in the figure, there was a significant association between BPPV and otolin-1 among the two groups.
Figure 3. Subgroups analysis was performed according to the reagent sources from China and American.
Figure 4. Subgroups analysis was performed according to differences in study populations.
Publication bias and sensitivity analysis
Egger's (p = 0.15) and Begg's tests (p = 0.13) indicated little to no publication bias. Similarly, funnel plot analysis showed minimal publication bias (Figure 5). Sensitivity analysis was also conducted using leave-one-out analyses and changing effect size. In addition, the results of the previous analyses were not altered by the exclusion of any articles, indicating good reliability and stability (Figure 6).
Figure 5. Funnel plot of the included studies in the meta-analysis. X-axis represents SMD, y-axis represents reciprocal of the natural log of SMD and the circles represent the included studies.
Figure 6. Sensitivity analysis of the included studies using leave-one-out analyses.
Discussion
In this meta-analysis, we assessed the relationship between BPPV and otolin-1 levels in serum, which showed higher levels of otolin-1 in patients with BPPV as compared with healthy controls. As such, otolin-1 may be a potential biomarker for diagnosing BPPV episodes.
Benign paroxysmal positional vertigo is the most common cause of vertigo, which is characterised by recurrent episodes that are triggered by changes in head position (5, 20). Although BPPV is benign and has a high rate of resolution, it affects the quality of life as patients report marked limitations in their daily activities (1, 21, 22). This is due to a high relapse rate of 7–50% (3, 4), which consequently causes anxiety, reduces the quality of life, and increases the risk of fall from instability (23, 24). Furthermore, BPPV comprises 24.1% of all clinical visits due to dizziness (2), and its medical burden is also known to be high (20, 25).
Most BPPV cases do not have a clear aetiology, with 75% of them being diagnosed as idiopathic (12, 26). Although the underlying pathophysiology of BPPV is yet to be fully elucidated, the main causes of BPPV have been proposed to be due to the degeneration of otoliths and displacement in the semicircular canal (6, 27). Otoconia consist of calcium carbonate deposits on a protein framework composed of otolin-1 and otoconin 90 (6, 11). The presence of calcium carbonate particles in the semicircular canal makes the canal sensitive to gravity, resulting in the dysfunctional sensation of angular acceleration (28). Thus, even if the current treatment strategies aim to minimise the impact of displaced otoconia for symptomatic relief, they do not address the degeneration of utricular otoconia, resulting in frequent recurrences.
From the clinical point of view, circulating biomarkers for otologic diseases are significant indicators for the investigation of inner ear damage, the diagnoses of inner ear disorders, tracking of treatment response, and the development of new treatments (11). Laboratory biomarkers should therefore be explored as tools to achieve a faster and more accurate diagnosis of BPPV, wherein otoconial degeneration may be utilised as a diagnostic modality (14, 25). Several recent studies have shown that inner ear-specific proteins are present in the blood serum and can be quantified (10, 29, 30). According to the literature search, eight proteins exclusive to the inner ear were identified, among which prestin and otolin-1 can be detected in the circulation (30). Prestin, a motor protein found in the lateral membrane of the outer hair cells (31), is known as a potential biomarker of noise- and drug-induced ototoxicity (10, 29, 32, 33).
Otolin-1 is a 70-kilodalton glycoprotein that acts as a scaffolding protein by attracting otoconial core matrix proteins and otoliths to the acellular gel matrix and inner ear sensory epithelia (11). Although otolin-1 exits in the endolymph, it can cross the labyrinth-blood barrier (10, 34), thus its detection and measurement in the peripheral blood are possible. Moreover, otolin-1 has been found to increase with age in healthy individuals and is significantly elevated in patients over 65 years or patients after mastoidectomy (12). This is consistent with previous scanning electron microscopy findings of age-related otoconial degeneration and reports of increased BPPV prevalence with age (6, 35, 36), making it a useful biomarker for the degeneration of otoconia (12). Elevated otolin-1 levels have also been reported in patients with BPPV, providing evidence for its potential as a biomarker for inner ear conditions and for predicting the risk of BPPV in the general population (17). Furthermore, studies have reported on the association between elevated serum otolin-1 levels and increased risk of BPPV relapse (25). The mechanism that the otolin-1 serum level is elevated in patients with BPPV is unclear. Some studies have shown that the level of otolin-1 is associated with calcium dysregulation (16, 37). From a practical standpoint, otolin-1 may be diagnostic in the management of the remaining 30% of challenging BPPV cases (10). The mechanism explaining why the otolin-1 serum level is elevated in patients with BPPV remains unclear. Further studies should be conducted with larger patient cohorts and dynamic assessments of otolin-1 levels in different stages to establish its value. Furthermore, suitable BPPV models should be established to study these metabolic processes in the near future.
Despite these findings, this meta-analysis has several limitations. First, the included papers were case–control studies, which are less credible than randomised controlled trials. Second, there was significant statistical heterogeneity among the studies. Owing to the small sample size and the fact that some of the studies were conducted on postmenopausal women, subgroup analysis by assay and menstruation status partially eliminated heterogeneity. This indicates that the reagents, oestrogen level, and age may have caused the heterogeneity in the meta-analysis. Third, language bias may have been present, since the studies were limited to those written in Chinese or English. Finally, this study is still in the initial phase. Since there was no identical standard for otolin-1 testing and no mention of the time from the symptom onset to blood sample collection, these nuances may have led to the differences in otolin-1 levels.
Conclusion
Serum otolin-1 levels in patients with BPPV were significantly higher than that of healthy controls and may serve as a biomarker for the diagnosis of BPPV episodes. Since the study is still in its initial phase, further investigations with larger sample sizes over extended periods should be conducted to monitor changes in blood otolin-1 levels, as well as facilitate the early identification and prevention of BPPV.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
XL and MZ have acquired and analysed the data and drafted the manuscript. MZ and KH have acquired and analysed the data and revised the manuscript. YW has conceptualised and supervised the study and revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Ningbo Medical Key Discipline (No. 2022- B12) and the Ningbo Natural Science Foundation (Grant No. 202003N4240).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Instrum RS, Parnes LS. Benign paroxysmal positional vertigo. Adv Otorhinolaryngol. (2019) 82:67–76. doi: 10.1159/000490273
2. Kim HJ, Lee, JO, Choi, JY, Kim, JS. Etiologic distribution of dizziness and vertigo in a referral-based dizziness clinic in South Korea. J Neurol. (2020) 267:2252–9. doi: 10.1007/s00415-020-09831-2
3. Chen J, Zhang S, Cui K, Liu C. Risk factors for benign paroxysmal positional vertigo recurrence: a systematic review and meta-analysis. J Neurol. (2021) 268:4117–27. doi: 10.1007/s00415-020-10175-0
4. Lindell E, Kollén L, Johansson M, Karlsson T, Rydén L, Falk E, et al. Benign paroxysmal positional vertigo, dizziness, and health-related quality of life among older adults in a population-based setting. Eur Arch Otorhinolaryngol. (2021) 78:1637–44. doi: 10.1007/s00405-020-06357-1
5. Kim J, Zee DS. Benign paroxysmal positional vertigo. New Engl J Med. (2014) 370:1138–47. doi: 10.1056/NEJMcp1309481
6. Walther LE, Wenzel A, Buder J, Bloching MB, Kniep R, Blödow A. Detection of human utricular otoconia degeneration in vital specimen and implications for benign paroxysmal positional vertigo. Eur Arch Otorhinolaryngol. (2014) 271:3133–8. doi: 10.1007/s00405-013-2784-6
7. Kao WTK, Parnes LS, Chole RA. Otoconia and otolithic membrane fragments within the posterior semicircular canal in benign paroxysmal positional vertigo. Laryngoscope. (2017) 127:709–14. doi: 10.1002/lary.26115
8. Von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D, et al. Benign paroxysmal positional vertigo: diagnostic criteria. J Vestib Res. (2015) 25:105–17. doi: 10.3233/VES-150553
9. Jahn K, Langhagen T. Heinen F. Vertigo and dizziness in children. Curr Opin Neurol. (2015) 28:78–82. doi: 10.1097/WCO.0000000000000157
10. Parham K, Sacks D, Bixby C, Fall P. Inner ear protein as a biomarker in circulation? Otolaryngol Head Neck Surg. (2014) 151:1038–40. doi: 10.1177/0194599814551127
11. Mulry E, Parham K. Inner ear proteins as potential biomarkers. Otol Neurotol. (2020) 41:145–52. doi: 10.1097/MAO.0000000000002466
12. Tabtabai R, Haynes L, Kuchel GA, Parham K. Age-Related increase in blood levels of otolin-1 in humans. Otol Neurotol. (2017) 38:865–9. doi: 10.1097/MAO.0000000000001426
13. Jang YS, Hwang CH, Shin JY, Bae WY, Kim LS. Age-related changes on the morphology of the otoconia. Laryngoscope. (2006) 116:996–1001. doi: 10.1097/01.mlg.0000217238.84401.03
14. Irugu DVK, Singh A, Yadav H, Verma H, Kumar R, Abraham RA, et al. Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study. J Laryngol Otol. (2021) 135:589–92. doi: 10.1017/S0022215121001274
15. Wu Y, Han W, Yan W, Lu X, Zhou M, Li L, et al. Increased otolin-1 in serum as a potential biomarker for idiopathic benign paroxysmal positional vertigo episodes. Front Neurol. (2020) 11:367. doi: 10.3389/fneur.2020.00367
16. Yadav H, Irugu D, Ramakrishanan L, Singh A, Abraham R, Sikka K, et al. An evaluation of serum Otolin-1 and Vitamin-D in benign paroxysmal positional vertigo. J Vestib Res. (2021) 31:433–40. doi: 10.3233/VES-201601
17. Qian S, Zhang X, Wang Y. Serum estradiol correlates with benign paroxysmal positional vertigo in postmenopausal women. Endocr Pract. (2022) 28:673–7. doi: 10.1016/j.eprac.2022.04.001
18. Feng MY, Zhuang JH, Gu HH, Tian Q, Zhang ZH. Changes of serum E2 and Otolin-1 levels in postmenopausal women with BPPV. J Clin Otorhinolaryngol Head Neck Surg. (2019) 33:1138–41, 47. doi: 10.13201/j.issn.1001-1781.2019.12.006
19. Norris JM, Simpson BS, Ball R, Freeman A, Kirkham A, Parry MA, et al. A modified Newcastle-Ottawa scale for assessment of study quality in genetic urological research. Eur Urol. (2021) 79:325–6. doi: 10.1016/j.eururo.2020.12.017
20. Kim H, Park J, Kim J. Update on benign paroxysmal positional vertigo. J Neurol. (2021) 268:1995–2000. doi: 10.1007/s00415-020-10314-7
21. Pereira AB, Santos JN, Volpe FM. Effect of Epley's maneuver on the quality of life of paroxismal positional benign vertigo patients. Braz J Otorhinolar. (2010) 76:704–8. doi: 10.1590/S1808-86942010000600006
22. Martens C, Goplen FK, Aasen T, Nordfalk KF, Nordahl SHG. Dizziness handicap and clinical characteristics of posterior and lateral canal BPPV. Eur Arch Otorhinolaryngol. (2019) 276:2181–9. doi: 10.1007/s00405-019-05459-9
23. Jumani K, Powell J. Benign paroxysmal positional vertigo: management and its impact on falls. Ann Otol Rhinol Laryngol. (2017) 126:602–5. doi: 10.1177/0003489417718847
24. Gunes A, Yuzbasioglu Y. Effects of treatment on anxiety levels among patients with benign paroxysmal positional vertigo. Eur Arch Otorhinolaryngol. (2019) 276:711–8. doi: 10.1007/s00405-019-05297-9
25. Fan Z, Hu Z, Han W, Lu X, Liu X, Zhou M, et al. High serum levels of otolin-1 in patients with benign paroxysmal positional vertigo predict recurrence. Front Neurol. (2022) 13:841677. doi: 10.3389/fneur.2022.841677
26. Soto-Varela A, Santos-Perez S, Rossi-Izquierdo M, Sanchez-Sellero I. Are the three canals equally susceptible to benign paroxysmal positional vertigo? Audiol Neurootol. (2013) 18:327–34. doi: 10.1159/000354649
27. Wu Y, Fan Z, Jin H, Guan Q, Zhou M, Lu X, et al. Assessment of bone metabolism in male patients with benign paroxysmal positional vertigo. Front Neurol. (2018) 9:742. doi: 10.3389/fneur.2018.00742
28. Sacks D, Parham K. Preliminary report on the investigation of the association between BPPV and osteoporosis using biomarkers. Otol Neurotol. (2015) 36:1532–6. doi: 10.1097/MAO.0000000000000853
29. Parham K, Dyhrfjeld-Johnsen J. Outer hair cell molecular protein, prestin, as a serum biomarker for hearing loss: proof of concept. Otol Neurotol. (2016) 37:1217–22. doi: 10.1097/MAO.0000000000001164
30. Naples J, Cox R, Bonaiuto G, Parham K. Prestin as an otologic biomarker of cisplatin ototoxicity in a guinea pig model. Otolaryngol Head Neck Surg. (2018) 158:541–6. doi: 10.1177/0194599817742093
31. Zheng J, Shen W, He DZ, Long KB, Madison LD, Dallos P. Prestin is the motor protein of cochlear outer hair cells. Nature. (2000) 405:149–55. doi: 10.1038/35012009
32. Sun C, Xuan X, Zhou Z, Yuan Y, Xue F. A preliminary report on the investigation of prestin as a biomarker for idiopathic sudden sensorineural hearing loss. Ear Nose Throat J. (2020) 99:528–31. doi: 10.1177/0145561319849949
33. Dogan M, Sahin M, Cetin N, Yilmaz M, Demirci B. Utilizing prestin as a predictive marker for the early detection of outer hair cell damage. Am J Otolaryngol. (2018) 39:594–8. doi: 10.1016/j.amjoto.2018.07.007
34. Deans MR, Peterson JM, Wong GW. Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1. PLoS ONE. (2010) 5:e12765. doi: 10.1371/journal.pone.0012765
35. Parham K, Kuchel GA. A geriatric perspective on benign paroxysmal positional vertigo. J Am Geriatr Soc. (2016) 64:378–85. doi: 10.1111/jgs.13926
36. Andrade LR, Lins U, Farina M, Kachar B, Thalmann R. Immunogold TEM of otoconin 90 and otolin – relevance to mineralization of otoconia, and pathogenesis of benign positional vertigo. Hearing Res. (2012) 292:14–25. doi: 10.1016/j.heares.2012.07.003
Keywords: BPPV, otolin-1, inner ear proteins, biomarker, meta-analysis
Citation: Liu X, Han K, Zhou M and Wu Y (2022) Association between otolin-1 and benign paroxysmal positional vertigo: A meta-analysis. Front. Neurol. 13:950023. doi: 10.3389/fneur.2022.950023
Received: 22 May 2022; Accepted: 09 November 2022;
Published: 15 December 2022.
Edited by:
Francisco Carlos Zuma E. Maia, Pontifical Catholic University of Rio Grande do Sul, BrazilReviewed by:
Tjasse Bruintjes, Gelre Hospitals, NetherlandsTakao Imai, Bell Land General Hospital, Japan
Copyright © 2022 Liu, Han, Zhou and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yunqin Wu, eXVucWluMTIxMjEyJiN4MDAwNDA7MTYzLmNvbQ==